Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius ... Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok(R), an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.07 | -4.34782608696 | 1.61 | 1.81 | 1.42 | 1122727 | 1.59498452 | CS |
| 4 | 0.602 | 64.1791044776 | 0.938 | 2.48 | 0.8822 | 2151030 | 1.58062365 | CS |
| 12 | 0.65 | 73.0337078652 | 0.89 | 2.48 | 0.65 | 2696185 | 1.37931715 | CS |
| 26 | -1.71 | -52.6153846154 | 3.25 | 3.4 | 0.65 | 1436426 | 1.40248099 | CS |
| 52 | -19.36 | -92.6315789474 | 20.9 | 26.25 | 0.65 | 2090144 | 5.87337833 | CS |
| 156 | -20.96 | -93.1555555556 | 22.5 | 42.75 | 0.65 | 1380982 | 15.24042484 | CS |
| 260 | -36.71 | -95.9738562092 | 38.25 | 114 | 0.65 | 2652424 | 40.43697414 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
